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Abstract
Background:  The best possible treatment of metastatic high grade large duodenal GIST is
controversial. Surgery (with or without segmental organ resection) remains the principal treatment
for primary and recurrent GIST. However, patients with advanced duodenal GIST have a high risk
of early tumour recurrence and short life expectancy.
Method: We present a case of a young man treated with a combined modality of surgery and
imatinib for an advanced duodenal GIST.
Results: He remains asymptomatic and disease free 42 months following this combined approach.
Conclusion: Treatment with imatinib has dramatically improved the outlook for patients with
advanced, unresectable and/or metastatic disease.
Background
Gastrointestinal stromal tumours or GISTs are the most
common mesenchymal neoplasms of the gastrointestinal
tract demonstrating positive c-kit (CD117) immunohisto-
chemical staining. Approximately 50–70% originates in
the stomach whereas 20–30% of from the small bowel,
with duodenum being the least common site. Less fre-
quent sites include the colon and rectum (5–15%) and
esophagus (< 5%). These tumours usually grow submu-
cosally but may also manifest as exophytic extraluminal
subserosal growth. We report a case of a young man with
a large extraluminal advanced duodenal GIST treated suc-
cessfully with combination of surgery and imatinib
mesylate.
Case report
A 56 year old man, who was on regular aspirin following
coronary artery bypass surgery, presented with an eight
month history of intermittent malaena requiring an emer-
gency admission to the hospital. At the time of admission
the only positive finding was that of pallor. His full blood
count revealed microcytic anaemia with haemoglobin of
7 g/dl. He was therefore transfused 4 units of packed red
cells. He underwent an urgent upper gastrointestinal
endoscopy which revealed a bulge in the 2nd part of the
duodenum without any visible mucosal abnormality or
intraluminal blood. The duodenal biopsies revealed mild
duodenitis and the CLO test for Helicobacter Pylori was
negative. A computerized tomography scan of the abdo-
men demonstrated a well demarcated enhancing 9.5 × 9.0
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cm mass arising from the lateral wall of the 2nd part of the
duodenum without any intra-abdominal lymphadenopa-
thy or liver metastases (Figure 1). A provisional diagnosis
of duodenal GIST was entertained. The patient underwent
an elective exploratory laparotomy which revealed a 10 ×
10 cm fleshy friable multi-lobulated exophytic mass aris-
ing from the anterior wall of the 2nd part of duodenum on
a narrow pedicle (Figure 2). Tumour deposits were also
seen on the adjacent mesocolon. A wedge excision of the
antimesenteric portion of the duodenum containing the
pedicle was performed (Figure 3, 4). A frozen section of
the duodenum was obtained to confirm tumour free mar-
gins before primarily closing it with 2/0 Vicryl in an inter-
rupted fashion. Also the adjacent mesocolon containing
tumour deposits was also excised and the defect closed
with interrupted sutures. The patient's postoperative
recovery was uneventful and he was discharged home
seven days later. Histopathology revealed that the tumour
consists of spindle cells which in areas were arranged in
fascicles. There was associated haemorrhage and the cells
exhibited moderate pleomorphism. Furthermore the duo-
denal margins were free from tumour (R0 resection).
Immunohistochemistry was strongly positive for CD117.
Moreover, the mesocolon deposits consists of spindle
shaped cells once again positive for CD117. The final
diagnosis was that of a high grade metastatic gastrointes-
tinal stromal tumour (GIST).
Because of size of the tumour, histopathological and
immunochemistry findings and the presence of tumour
deposits in the adjacent mesocolon, the patient was given
two years of imatinib mesylate therapy. A follow-up CT
scans of chest, abdomen and pelvis have failed to reveal
any evidence of recurrence. The patient is still alive and
well without any signs of recurrence 42 months following
this treatment.
CT scan of patient showing duodenal GIST Figure 1
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Discussion
Duodenal GIST can present with vague and non-specific
symptoms such as upper abdominal pain (50% to 70%),
gastrointestinal haemorrhage (20% to 50%) and an
abdominal mass [1,2]. A patient presenting with gastroin-
testinal haemorrhage may reveal a submucosal mass on
endoscopy and biopsies are diagnostic in only 50% of
cases [3]. In our patient the endoscopy and biopsies were
not helpful because the tumour was subserosal. The CT
scan however raised the suspicion of duodenal GIST.
At laparotomy a large duodenal tumour on a narrow pedi-
cle was encountered. It was felt that a wedge duodenal
resection would be adequate provided tumour free mar-
gins could be obtained. A frozen section confirmed histo-
logic tumour-free margins. Furthermore the adjacent
mesocolon containing tumour deposit was also excised.
Table 1: Parameters used in evaluation of GIST malignancy
Authors (year) Site Size Mitosis Histological Type Cytological Atypia Necrosis
Amin MB et al (1993)5 -+ + - - -
Kindblom et al (1998)6 -- + - + +
Fletcher et al (1998)7 -- + + + -
Panizo et al (2000)8 -+ + - - -
Trupiano et al (2002)9 -+ + + + -
Miettinen et al (2002)10 ++ + - - -
Intra-operative view of the duodenal GIST Figure 2
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There is a wide variation in the clinical behaviour of gas-
trointestinal GIST's, most being benign. However, small
bowel (jejunum, duodenum and the ileum) GISTs which
constitute 20% to 30% of gastrointestinal stromal
tumours have a high propensity for malignant behaviour
[4]. The factors used in evaluation of GIST are summa-
rized in Table 1[5-10]. Certainly larger size tumours with
high mitotic figures, cytological atypia, necrosis and pleo-
morphism favours malignancy. Our patients had all such
features along with implantation over the adjacent meso-
colon and therefore it was considered not only high grade
but metastatic in nature.
The overall 5 year survival for completely resected GISTs
ranges from 30 – 80% [11]. The relapse rate for patients
having surgery ranges from 5% in those that have a com-
plete resection, to 90% in those with unresectable and/or
metastatic disease. The median survival for patients with
unresectable and/or metastatic disease is 12 months
(ranging from 2–20 months) [12]. Patients with advanced
stage disease have shown that the disease progresses after
approximately 1.5 months without effective therapy [13].
Imatinib mesylate, a specific tyrosine kinase inhibitor, is
one of the first targeted molecular therapies, and works by
disrupting specific aspects of tumour growth. This treat-
ment has revolutionised the treatment of unresectable
and/or metastatic GIST. Following the successful treat-
ment of a Finish patient with imatinib in a chemotherapy-
resistant metastatic GIST [14], a number of studies have
shown encouraging results with imatinib. In a large rand-
omized multicentre trial conducted by Demetri et al [15],
imatinib induced a sustained objective response in over
half of patients with advanced unresectabe or metastatic
GIST. The estimated one year survival was 88%. A number
of other trials [16-19] similarly have shown good
response rate and survival in patients with advanced GIST
(Table 2).
Post resectional view with primary closure of the duodenum Figure 3
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We felt that our patient being at an increased risk of recur-
rence because of his operative and histological findings,
would need adjuvant treatment with imatinib (a) to stabi-
lise his disease and (b) to prolong his recurrence-free
period and survival. He was therefore started on 400 mg
of imatinib once daily. He was followed up at six monthly
Table 2: Summary of Imatinib Trials
Trial Source Phase Patients no Imatinib 
Dosage
Follow-up Response Rate
Multicentre Randomized USA Trial Demetri et al NEJM 200215 II 147 400 mg od
600 mg od
34 months median CR 1%
PR – 67%
SD – 16%
Survival – median
NR
EORTC, ISG and AGITG Van Glabbeke M et al Eur J Cancer16,17 III 946 400 mg od
400 mg bid
17 months median CR – 6%
PR – 45%
SD – 33%
Survival – median
NR
The Sarcoma Intergroup Rankin et al Journal of Clinical Oncology 200418 III 746 400 mg od
800 mg od
24 months median CR – 3%
PR – 45%
SD – 26%
Survival – median
NR
EORTC Van Oosterum, Lancet 200119 I/II 40 Dose finding 
400–1000 mg od
9–13 months PR – 53%
SD – 16%
CR – complete response, NR – Not reached, PR – partial response, SD – stable disease
Macroscopic appearance of duodenal GIST specimen Figure 4
Macroscopic appearance of duodenal GIST specimen.Publish with BioMed Central    and   every 
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intervals with a full body CT scan for the first two years.
Surprisingly enough, he did not suffer from any major
side effects from imatinib at all. At two years imatinib was
stopped and further CT scans were performed at six
monthly intervals which have not shown any evidence of
recurrence and the patient remains asymptomatic and dis-
ease free at 42 months following his treatment. The future
plan is to monitor him closely with CT scans for another
eighteen months.
Conclusion
We feel that imatinib, a targeted tyrosine kinase inhibitor
treatment in combination with surgery, has prolonged
our patient's disease free survival and therefore have pro-
vided an effective adjuvant treatment for the metastatic
duodenal GIST.
Conflict of interest/funding
The author(s) declare that they have no competing inter-
ests.
References
1. Sturgeon C, Chejfec G, Espat NJ: Gastrointestinal stromal
tumors: a spectrum of disease.  Surg Oncol 2003, 12:21-26.
2. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan
MF:  Two hundred gastrointestinal stromal tumors: recur-
rence patterns and prognostic factors for survival.  Ann Surg
2000, 231:51-58.
3. Chack A, Canto MI, Rosch T: Endoscopic differentiation of
benign and malignant stromal cell tumors.  Gastrointestinal
Endosc 1997, 45:468-473.
4. DeMatteo RP, Heinrich MC, El-Rifai WM, Demetri G: Clinical man-
agement of gastrointestinal stromal tumors: Before and
after STI-571.  Human Pathol 2002, 33:466-67.
5. Amin MB, Ma CK, Linden MD, Kubus JJ, Zarbo RJ: Prognostic value
of proliferating cell nuclear antigen index in gastric stromal
tumors. Correlation with mitotic count and clinical out-
come.  Am J Clin Pathol 1993, 100:428-32.
6. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM: Gas-
trointestinal pacemaker cell tumor (GIPACT): gastrointes-
tinal stromal tumors show phenotypic characteristics of the
interstitial cells of Cajal.  Am J Pathol 1998, 152:1259-1269.
7. De Saint Aubain Somerhausen N, Fletcher CDM: Gastrointestinal
Stromal Tumors. An Update.  Sarcoma 1998, 2:133-141.
8. Panizo-Santos A, Sola I, Vega F, de Alava E, Lozano MD, Idoate MA,
Pardo-Mindan J: Predicting Metastatic Risk of Gastrointestinal
Stromal Tumors: Role of Cell Proliferation and Cell Cycle
Regulatory Proteins.  Int J Surg Pathol 2000, 8:133-44.
9. Trupiano JK, Stewart RE, Misick C, Appelman HD, Goldblum JR: Gas-
tric stromal tumors: a clinicopathologic study of 77 cases
with correlation of features with nonaggressive and aggres-
sive clinical behaviors.  Am J Surg Pathol 2002, 26:705-14.
10. Miettinen M, El-Rifai W, H L, Sobin L, Lasota J: Evaluation of malig-
nancy and prognosis of gastrointestinal stromal tumors: a
review.  Hum Pathol 2002, 33:478-83.
11. Casper ES: Gastrointestinal stromal tumors.  Curr Treat Options
Oncol 2000, 1:267-273.
12. Roberts PJ, Eisenberg B: Clinical presentation of gastrointesti-
nal stromal tumors and treatment of operable disease.  Eur J
Cancer 2002, 38(suppl 5):S37-38.
13. Singer S, Rubin BP, Lux ML, Chen CJ, Demetri GD, Fletcher CD,
Fletcher JA: Prognostic value of KIT mutation type, mitotic
activity, and histologic subtype in gastrointestinal stromal
tumors.  J Clin Oncol 20:3898-905. 2002 Sep 15
14. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahar-
tiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker
B, Demetri GD: Effect of the tyrosine kinase inhibitor STI571
in a patient with a metastatic gastrointestinal stromal
tumor.  N Engl J Med 2001, 344:1052-56.
15. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisen-
berg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M,
Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng
B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H: Effi-
cacy and safety of imatinib mesylate in advanced gastrointes-
tinal stromal tumors.  N Engl J Med 2002, 347:472-80.
16. Van Glabbeke M, Verweij J, Casali PG, Simes J, Le Cesne A, Reichardt
P, Issels R, Judson IR, van Oosterom AT, Blay JY: Predicting toxic-
ities for patients with advanced gastrointestinal stromal
tumours treated with imatinib: a study of the European
Organisation for Research and Treatment of Cancer, the
Italian Sarcoma Group, and the Australasian Gastro-Intesti-
nal Trials Group (EORTC-ISG-AGITG).  Eur J Cancer 2006,
42:2277-85.
17. Silberman S, Joensuu H: Overview of issues related to imatinib
therapy of advanced gastrointestinal stromal tumours: a dis-
cussion amongst experts.  Eur J Cancer 2002, 38(suppl
5):S66-S69.
18. Rankin C, Von Mehren M, Blanke C, Benjamin R, D C, Fletcher M,
Bramwell V, Crowley J, Borden E, D G: Demetri. Dose effect of
imatinib (IM) in patients (pts) with metastatic GIST – Phase
III Sarcoma Group Study S0033.  J Clin Oncol 2004,
22(14S):9005.
19. van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola
E, Dimitrijevic S, Martens M, Webb A, Sciot R, Van Glabbeke M, Sil-
berman S, Nielsen OS, European Organisation for Research and
Treatment of Cancer Soft Tissue and Bone Sarcoma Group: Safety
and efficacy of imatinib (STI571) in metastatic gastrointesti-
nal stromal tumours: a phase I study.  Lancet 2001,
358:1421-1423.